Ajinomoto (2802) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
9 Jul, 2026Executive summary
Achieved record Q1 FY2024 revenue of ¥365.5 billion, up 7.7% year-over-year, with business profit rising 0.5% to ¥43.0 billion; profit growth was 7% excluding the Forge acquisition impact.
Profit attributable to owners declined 12% year-over-year to ¥23.9 billion, mainly due to a transient increase in overseas withholding tax from fund repatriation.
Strategic investments increased company-wide expenses in Q1 to support the 2030 Roadmap, but full-year expenses are expected to remain within initial forecasts.
No revision to the full-year forecast announced in May 2024; management remains confident in achieving full-year targets.
Financial highlights
Sales revenue reached ¥365.5 billion, up ¥25.9 billion or 7.7% year-over-year; excluding currency effects and Forge, revenue was up about 7%.
Business profit was ¥43.0 billion, up ¥0.2 billion; excluding Forge, up about 7% year-over-year.
Gross profit improved by ¥9.5 billion year-over-year to ¥133.4 billion, driven by sales growth.
Basic EPS was ¥46.98, down from ¥51.77 year-over-year.
Comprehensive income dropped 18.1% year-over-year to ¥71.9 billion.
Outlook and guidance
Full-year expense control is planned to align with initial forecasts despite higher Q1 spending.
Price hikes for domestic coffee and seasonings are expected to support profit recovery in subsequent quarters.
Gradual improvement in CDMO and amino acids segments anticipated from Q2 onward, with no revision to full-year forecasts.
Dividend forecast for FY2025 is ¥80.00 per share, up from ¥74.00 in FY2024.
Management remains confident in achieving full-year targets, with upside potential if current trends continue.
Latest events from Ajinomoto
- Doubling medical food sales by 2030 through 20%+ growth, innovation, and global expansion.2802
Investor update8 Jul 2026 - AI-driven growth boosts ABF/ABF™ demand, margins, and capacity through innovation and investment.2802
Investor update3 Jul 2026 - Record sales and profit growth led to upward forecasts and increased shareholder returns.2802
Q2 20251 Jul 2026 - Record sales and profit highs, with raised full-year profit outlook and strong segment momentum.2802
Q3 202630 Jun 2026 - Global leader in amino acid science targets growth, health impact, and major sustainability gains.2802
Investor presentation30 Jun 2026 - Record profit and sales growth achieved, with further gains targeted amid managed global risks.2802
Q4 202613 May 2026 - Integrated sustainability and agri-food innovation drive growth and aim to double key solution sales by 2030.2802
Investor Day 20266 May 2026 - Governance, compensation, and management reforms drive long-term growth and value creation.2802
Investor update9 Apr 2026 - Record sales and profit growth led by overseas, healthcare, and currency gains amid cost pressures.2802
Q3 20259 Jan 2026